| 前收盘价格 | 19.68 |
| 收盘价格 | 19.58 |
| 成交量 | 42,186,458 |
| 平均成交量 (3个月) | 46,458,419 |
| 市值 | 81,115,054,080 |
| 市盈率 (P/E TTM) | 28.70 |
| 预期市盈率 (P/E Forward) | 15.58 |
| 价格/销量 (P/S) | 4.26 |
| 股市价格/股市净资产 (P/B) | 1.87 |
| 52周波幅 | |
| 利润日期 | 24 Mar 2025 - 28 Mar 2025 |
| 营业毛利率 | 15.38% |
| 营业利益率 (TTM) | 21.22% |
| 稀释每股收益 (EPS TTM) | 0.640 |
| 季度收入增长率 (YOY) | 1.00% |
| 季度盈利增长率 (YOY) | -33.90% |
| 总债务/股东权益 (D/E MRQ) | 10.23% |
| 流动比率 (MRQ) | 2.91 |
| 营业现金流 (OCF TTM) | 3.22 B |
| 杠杆自由现金流 (LFCF TTM) | -982.72 M |
| 资产报酬率 (ROA TTM) | 3.98% |
| 股东权益报酬率 (ROE TTM) | 7.20% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (HK) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | WUXI BIO | - | - |
AIStockmoo 评分
-0.4
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | 2.0 |
| 平均 | -0.38 |
相关股票
| 股票 | 市值 | DY | P/E（TTM） | P/B |
|---|---|---|---|---|
| WUXI BIO | 81 B | - | 28.70 | 1.87 |
| BEIGENE | 195 B | - | - | 6.93 |
| SINO BIOPHARM | 52 B | 1.92% | 22.08 | 1.48 |
| PHARMARON | 46 B | 1.60% | 12.70 | 1.66 |
| AKESO | 55 B | - | - | 9.50 |
| INNOVENT BIO | 53 B | - | - | 4.54 |
|
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has a global revenue of CNY 17 billion. North America represented 47.4% of total revenue in 2023. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual sourcing strategy by providing drug products and drug substance manufacturing. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Large Core |
| 内部持股比例 | 14.80% |
| 机构持股比例 | 34.98% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合